<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661661</url>
  </required_header>
  <id_info>
    <org_study_id>A3921041</org_study_id>
    <nct_id>NCT00661661</nct_id>
  </id_info>
  <brief_title>Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan</brief_title>
  <official_title>A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term effectiveness and safety of
      CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this
      study after they have completed participation in another &quot;qualifying&quot; study of CP-690,550.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to the last participants visit in the study. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for safety evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Assessment of Arthritis Pain</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender/Painful Joint Counts</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>This was carried out on 68 joints. Each joint's response to pressure/motion was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Counts</measure>
    <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
    <description>Sixty-six (66) joints, the same as those assessed for tenderness/pain except for the right and left hip joints, were assessed for swelling by palpation using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Physical Functioning</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Physical</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Bodily Pain</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_General Health</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Vitality</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Social Functioning</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Emotional</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Mental Health</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Physical</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Mental</measure>
    <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Month 24 in Study A3921044 in Modified Total Sharp Score (mTSS)</measure>
    <time_frame>First visit in the study (Month 24 in Study A3921044), Weeks 24, 48, and 96</time_frame>
    <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented potential improvement. Month 24 (the final visit) in Study A3921044 was taken as the first visit in current study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">487</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CP-690,550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>5 mg BID up to 10 mg BID until launch</description>
    <arm_group_label>CP-690,550</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed their participation in a randomized &quot;qualifying&quot; study of
             CP-690,550 for the treatment of rheumatoid arthritis

        Exclusion Criteria:

          -  Serious medical conditions that would make treatment with CP-690,550 potentially
             unsafe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba-ken Saiseikai Narashino Hospital</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <zip>275-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimoshizu National Hospital</name>
      <address>
        <city>Yotukaidou</city>
        <state>Chiba</state>
        <zip>284-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aso Iizuka Hospital</name>
      <address>
        <city>Iiduka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health Hospital</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHONO Rheumatism Clinic</name>
      <address>
        <city>Sawara-ku</city>
        <state>Fukuoka</state>
        <zip>814-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Hospital</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashihiroshima Memorial Hospital</name>
      <address>
        <city>Higashihiroshima</city>
        <state>Hiroshima</state>
        <zip>739-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Red Cross Hospital &amp; Atomic-bomb Survivors Hospital</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <zip>730-8619</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katayama Orthopedic Rheumatology Clinic</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo city general hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Medical Center for Rheumatic Diseases</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>063-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taga General Hospital</name>
      <address>
        <city>Hitachi-shi</city>
        <state>Ibaraki</state>
        <zip>316-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Koushi</city>
        <state>Kumamoto</state>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National hospital Organization Mie Chuou Medical Center</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hikarigaoka Spellman Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Ohmura</city>
        <state>Nagasaki</state>
        <zip>856-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasebo Chuo Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higami hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka Minami Center</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ureshino Medical Center</name>
      <address>
        <city>Ureshino</city>
        <state>Saga</state>
        <zip>843-0393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Kitasato Institute Medical Center Hospital</name>
      <address>
        <city>Kitamoto</city>
        <state>Saitama</state>
        <zip>364-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Medical Center East</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <zip>116-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Hospital, Faculty of Medicine</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasaki Foundation Kyoundo Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo Tokyo Koto Geriatric Medical Center</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization MURAYAMA Medical Center</name>
      <address>
        <city>Musashimurayama-shi</city>
        <state>Tokyo</state>
        <zip>208-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuhara Hospital</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>155-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University, Institute of Rheumatology</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chiba-East Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kondo clinic for rheumatism and orthopaedics</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co.LTA PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukusima Daiichi Hospital</name>
      <address>
        <city>Fukusima</city>
        <zip>960-8251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Rheumatology Clinic</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Orthopaedic Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Taihaku Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>982-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital of Medicine and Dentistry</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A Medical Corporation Oribe Rheumatism Internist Clinic</name>
      <address>
        <city>Oita</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tazuke Kofukai Medical Research Institute Kitano Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama city hospital</name>
      <address>
        <city>Saitama</city>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921041&amp;StudyName=Long-Term%2C%20Open-Label%20Study%20Of%20CP-690%2C550%20For%20Treatment%20Of%20Rheumatoid%20Arthritis%20In%20Japan</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>February 17, 2015</results_first_submitted>
  <results_first_submitted_qc>April 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long term open label study in Japan</keyword>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>tofacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants received study drug (CP-690,550 or placebo) in the precedent study A3921039 (NCT00603512) for 12 weeks, A3921040 (NCT00687193) for 12 weeks, or A3921044 (NCT00847613) for 2 years.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not assigned treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="381"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="486"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="11.2"/>
                    <measurement group_id="B2" value="49.3" spread="11.7"/>
                    <measurement group_id="B3" value="52.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=373, 105, 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1"/>
                    <measurement group_id="O2" value="70.5"/>
                    <measurement group_id="O3" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="72.4"/>
                    <measurement group_id="O3" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="77.1"/>
                    <measurement group_id="O3" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="85.6"/>
                    <measurement group_id="O3" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="87.3"/>
                    <measurement group_id="O3" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="88.2"/>
                    <measurement group_id="O3" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                    <measurement group_id="O2" value="87.0"/>
                    <measurement group_id="O3" value="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                    <measurement group_id="O2" value="92.0"/>
                    <measurement group_id="O3" value="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="88.8"/>
                    <measurement group_id="O3" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                    <measurement group_id="O2" value="84.8"/>
                    <measurement group_id="O3" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="86.8"/>
                    <measurement group_id="O3" value="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 73, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="84.9"/>
                    <measurement group_id="O3" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5"/>
                    <measurement group_id="O2" value="82.9"/>
                    <measurement group_id="O3" value="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="86.0"/>
                    <measurement group_id="O3" value="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="90.0"/>
                    <measurement group_id="O3" value="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1"/>
                    <measurement group_id="O2" value="84.6"/>
                    <measurement group_id="O3" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="36.2"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=373, 105, 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4"/>
                    <measurement group_id="O2" value="47.6"/>
                    <measurement group_id="O3" value="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8"/>
                    <measurement group_id="O2" value="46.7"/>
                    <measurement group_id="O3" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="56.9"/>
                    <measurement group_id="O3" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="59.8"/>
                    <measurement group_id="O3" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="64.1"/>
                    <measurement group_id="O3" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="60.9"/>
                    <measurement group_id="O3" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9"/>
                    <measurement group_id="O2" value="72.6"/>
                    <measurement group_id="O3" value="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                    <measurement group_id="O2" value="68.8"/>
                    <measurement group_id="O3" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2"/>
                    <measurement group_id="O2" value="72.2"/>
                    <measurement group_id="O3" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1"/>
                    <measurement group_id="O2" value="69.7"/>
                    <measurement group_id="O3" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 73, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="65.8"/>
                    <measurement group_id="O3" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2"/>
                    <measurement group_id="O2" value="71.9"/>
                    <measurement group_id="O3" value="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="53.8"/>
                    <measurement group_id="O3" value="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="19.0"/>
                    <measurement group_id="O3" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=373, 105, 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9"/>
                    <measurement group_id="O2" value="38.4"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="40.5"/>
                    <measurement group_id="O3" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 73, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="41.1"/>
                    <measurement group_id="O3" value="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4"/>
                    <measurement group_id="O2" value="56.7"/>
                    <measurement group_id="O3" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.03"/>
                    <measurement group_id="O2" value="-0.44" spread="0.05"/>
                    <measurement group_id="O3" value="-0.53" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.03"/>
                    <measurement group_id="O2" value="-0.45" spread="0.05"/>
                    <measurement group_id="O3" value="-0.57" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.03"/>
                    <measurement group_id="O2" value="-0.49" spread="0.05"/>
                    <measurement group_id="O3" value="-0.62" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.03"/>
                    <measurement group_id="O2" value="-0.51" spread="0.05"/>
                    <measurement group_id="O3" value="-0.63" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.03"/>
                    <measurement group_id="O2" value="-0.55" spread="0.05"/>
                    <measurement group_id="O3" value="-0.65" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.03"/>
                    <measurement group_id="O2" value="-0.54" spread="0.05"/>
                    <measurement group_id="O3" value="-0.66" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.03"/>
                    <measurement group_id="O2" value="-0.62" spread="0.05"/>
                    <measurement group_id="O3" value="-0.68" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.03"/>
                    <measurement group_id="O2" value="-0.57" spread="0.05"/>
                    <measurement group_id="O3" value="-0.67" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.03"/>
                    <measurement group_id="O2" value="-0.60" spread="0.05"/>
                    <measurement group_id="O3" value="-0.69" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.04"/>
                    <measurement group_id="O2" value="-0.61" spread="0.05"/>
                    <measurement group_id="O3" value="-0.69" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.04"/>
                    <measurement group_id="O2" value="-0.61" spread="0.06"/>
                    <measurement group_id="O3" value="-0.69" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.04"/>
                    <measurement group_id="O2" value="-0.64" spread="0.06"/>
                    <measurement group_id="O3" value="-0.69" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.04"/>
                    <measurement group_id="O2" value="-0.63" spread="0.06"/>
                    <measurement group_id="O3" value="-0.68" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.04"/>
                    <measurement group_id="O2" value="-0.64" spread="0.06"/>
                    <measurement group_id="O3" value="-0.68" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.04"/>
                    <measurement group_id="O2" value="-0.59" spread="0.07"/>
                    <measurement group_id="O3" value="-0.65" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.04"/>
                    <measurement group_id="O2" value="-0.62" spread="0.06"/>
                    <measurement group_id="O3" value="-0.66" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.04"/>
                    <measurement group_id="O2" value="-0.57" spread="0.07"/>
                    <measurement group_id="O3" value="-0.65" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.08"/>
                    <measurement group_id="O3" value="-0.68" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.05"/>
                    <measurement group_id="O2" value="-0.61" spread="0.09"/>
                    <measurement group_id="O3" value="-0.67" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.06"/>
                    <measurement group_id="O2" value="-0.67" spread="0.09"/>
                    <measurement group_id="O3" value="-0.67" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.06"/>
                    <measurement group_id="O2" value="-0.42" spread="0.09"/>
                    <measurement group_id="O3" value="-0.59" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.06"/>
                    <measurement group_id="O2" value="-0.25" spread="0.10"/>
                    <measurement group_id="O3" value="-0.59" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.06"/>
                    <measurement group_id="O2" value="-0.33" spread="0.14"/>
                    <measurement group_id="O3" value="-0.64" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.07"/>
                    <measurement group_id="O2" value="-0.25" spread="0.12"/>
                    <measurement group_id="O3" value="-0.65" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.07"/>
                    <measurement group_id="O2" value="-0.23" spread="0.07"/>
                    <measurement group_id="O3" value="-0.62" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.11"/>
                    <measurement group_id="O2" value="-0.63">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-0.82" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.37"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-0.96" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
        <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
          <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="0.07"/>
                    <measurement group_id="O2" value="-1.94" spread="0.13"/>
                    <measurement group_id="O3" value="-2.45" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="0.07"/>
                    <measurement group_id="O2" value="-1.95" spread="0.13"/>
                    <measurement group_id="O3" value="-2.59" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 104, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.06"/>
                    <measurement group_id="O2" value="-2.14" spread="0.12"/>
                    <measurement group_id="O3" value="-2.77" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.01" spread="0.06"/>
                    <measurement group_id="O2" value="-2.08" spread="0.12"/>
                    <measurement group_id="O3" value="-2.81" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.12" spread="0.06"/>
                    <measurement group_id="O2" value="-2.42" spread="0.12"/>
                    <measurement group_id="O3" value="-2.96" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="0.07"/>
                    <measurement group_id="O2" value="-2.54" spread="0.13"/>
                    <measurement group_id="O3" value="-3.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="0.07"/>
                    <measurement group_id="O2" value="-2.72" spread="0.13"/>
                    <measurement group_id="O3" value="-3.08" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 101, 424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.07"/>
                    <measurement group_id="O2" value="-2.80" spread="0.12"/>
                    <measurement group_id="O3" value="-3.15" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="0.07"/>
                    <measurement group_id="O2" value="-2.83" spread="0.12"/>
                    <measurement group_id="O3" value="-3.11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.26" spread="0.07"/>
                    <measurement group_id="O2" value="-2.86" spread="0.14"/>
                    <measurement group_id="O3" value="-3.17" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.07"/>
                    <measurement group_id="O2" value="-2.87" spread="0.14"/>
                    <measurement group_id="O3" value="-3.13" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 83, 342)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="0.08"/>
                    <measurement group_id="O2" value="-2.83" spread="0.15"/>
                    <measurement group_id="O3" value="-3.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 79, 321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" spread="0.08"/>
                    <measurement group_id="O2" value="-2.78" spread="0.14"/>
                    <measurement group_id="O3" value="-3.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="0.08"/>
                    <measurement group_id="O2" value="-2.84" spread="0.15"/>
                    <measurement group_id="O3" value="-3.07" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="0.09"/>
                    <measurement group_id="O2" value="-2.84" spread="0.16"/>
                    <measurement group_id="O3" value="-3.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=218, 72, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.08" spread="0.09"/>
                    <measurement group_id="O2" value="-2.84" spread="0.16"/>
                    <measurement group_id="O3" value="-3.02" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="0.09"/>
                    <measurement group_id="O2" value="-2.87" spread="0.17"/>
                    <measurement group_id="O3" value="-3.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=178, 56, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.10"/>
                    <measurement group_id="O2" value="-3.06" spread="0.19"/>
                    <measurement group_id="O3" value="-3.18" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="0.11"/>
                    <measurement group_id="O2" value="-3.07" spread="0.19"/>
                    <measurement group_id="O3" value="-3.15" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" spread="0.12"/>
                    <measurement group_id="O2" value="-3.35" spread="0.25"/>
                    <measurement group_id="O3" value="-3.26" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="0.13"/>
                    <measurement group_id="O2" value="-2.44" spread="0.44"/>
                    <measurement group_id="O3" value="-3.09" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.08" spread="0.17"/>
                    <measurement group_id="O2" value="-2.25" spread="0.58"/>
                    <measurement group_id="O3" value="-3.02" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="0.15"/>
                    <measurement group_id="O2" value="-2.61" spread="0.70"/>
                    <measurement group_id="O3" value="-3.17" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="0.15"/>
                    <measurement group_id="O2" value="-1.81" spread="0.51"/>
                    <measurement group_id="O3" value="-3.23" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="0.15"/>
                    <measurement group_id="O2" value="-2.09" spread="0.45"/>
                    <measurement group_id="O3" value="-3.23" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=21, 1, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.34" spread="0.25"/>
                    <measurement group_id="O2" value="-2.15">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-3.29" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.51"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-2.95" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
        <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
          <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="0.06"/>
                    <measurement group_id="O2" value="-1.90" spread="0.12"/>
                    <measurement group_id="O3" value="-2.32" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="0.06"/>
                    <measurement group_id="O2" value="-1.90" spread="0.12"/>
                    <measurement group_id="O3" value="-2.41" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="0.06"/>
                    <measurement group_id="O2" value="-2.06" spread="0.11"/>
                    <measurement group_id="O3" value="-2.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" spread="0.06"/>
                    <measurement group_id="O2" value="-1.97" spread="0.11"/>
                    <measurement group_id="O3" value="-2.57" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="0.06"/>
                    <measurement group_id="O2" value="-2.29" spread="0.11"/>
                    <measurement group_id="O3" value="-2.72" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=337, 102, 439)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="0.06"/>
                    <measurement group_id="O2" value="-2.45" spread="0.11"/>
                    <measurement group_id="O3" value="-2.81" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="0.06"/>
                    <measurement group_id="O2" value="-2.58" spread="0.12"/>
                    <measurement group_id="O3" value="-2.84" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=322, 102, 424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="0.06"/>
                    <measurement group_id="O2" value="-2.60" spread="0.11"/>
                    <measurement group_id="O3" value="-2.85" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="0.06"/>
                    <measurement group_id="O2" value="-2.61" spread="0.11"/>
                    <measurement group_id="O3" value="-2.86" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.98" spread="0.06"/>
                    <measurement group_id="O2" value="-2.70" spread="0.12"/>
                    <measurement group_id="O3" value="-2.92" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.07"/>
                    <measurement group_id="O2" value="-2.69" spread="0.13"/>
                    <measurement group_id="O3" value="-2.88" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 83, 342)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="0.07"/>
                    <measurement group_id="O2" value="-2.64" spread="0.13"/>
                    <measurement group_id="O3" value="-2.86" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="0.07"/>
                    <measurement group_id="O2" value="-2.60" spread="0.13"/>
                    <measurement group_id="O3" value="-2.88" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=231, 79, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.07"/>
                    <measurement group_id="O2" value="-2.66" spread="0.13"/>
                    <measurement group_id="O3" value="-2.83" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.90" spread="0.08"/>
                    <measurement group_id="O2" value="-2.68" spread="0.14"/>
                    <measurement group_id="O3" value="-2.85" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.08"/>
                    <measurement group_id="O2" value="-2.70" spread="0.14"/>
                    <measurement group_id="O3" value="-2.81" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.90" spread="0.08"/>
                    <measurement group_id="O2" value="-2.68" spread="0.15"/>
                    <measurement group_id="O3" value="-2.84" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="0.09"/>
                    <measurement group_id="O2" value="-2.80" spread="0.17"/>
                    <measurement group_id="O3" value="-2.89" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="0.09"/>
                    <measurement group_id="O2" value="-2.84" spread="0.16"/>
                    <measurement group_id="O3" value="-2.91" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.11"/>
                    <measurement group_id="O2" value="-3.05" spread="0.22"/>
                    <measurement group_id="O3" value="-2.97" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="0.12"/>
                    <measurement group_id="O2" value="-2.46" spread="0.34"/>
                    <measurement group_id="O3" value="-2.87" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.17"/>
                    <measurement group_id="O2" value="-2.38" spread="0.44"/>
                    <measurement group_id="O3" value="-2.81" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="0.13"/>
                    <measurement group_id="O2" value="-2.36" spread="0.57"/>
                    <measurement group_id="O3" value="-2.92" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" spread="0.14"/>
                    <measurement group_id="O2" value="-1.89" spread="0.42"/>
                    <measurement group_id="O3" value="-3.00" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=58, 5, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.13" spread="0.15"/>
                    <measurement group_id="O2" value="-1.86" spread="0.30"/>
                    <measurement group_id="O3" value="-3.03" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" spread="0.24"/>
                    <measurement group_id="O2" value="-1.50">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-3.16" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" spread="0.27"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-2.67" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Arthritis</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Arthritis</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.52" spread="1.38"/>
                    <measurement group_id="O2" value="-25.38" spread="2.43"/>
                    <measurement group_id="O3" value="-32.54" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.81" spread="1.36"/>
                    <measurement group_id="O2" value="-25.34" spread="2.61"/>
                    <measurement group_id="O3" value="-35.06" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.61" spread="1.35"/>
                    <measurement group_id="O2" value="-28.86" spread="2.31"/>
                    <measurement group_id="O3" value="-37.24" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.31" spread="1.38"/>
                    <measurement group_id="O2" value="-27.33" spread="2.23"/>
                    <measurement group_id="O3" value="-36.67" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.67" spread="1.39"/>
                    <measurement group_id="O2" value="-30.75" spread="2.53"/>
                    <measurement group_id="O3" value="-38.43" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.70" spread="1.42"/>
                    <measurement group_id="O2" value="-29.95" spread="2.63"/>
                    <measurement group_id="O3" value="-38.98" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.03" spread="1.46"/>
                    <measurement group_id="O2" value="-32.48" spread="2.56"/>
                    <measurement group_id="O3" value="-39.02" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.79" spread="1.44"/>
                    <measurement group_id="O2" value="-34.33" spread="2.42"/>
                    <measurement group_id="O3" value="-40.00" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.30" spread="1.53"/>
                    <measurement group_id="O2" value="-35.38" spread="2.31"/>
                    <measurement group_id="O3" value="-39.88" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.29" spread="1.53"/>
                    <measurement group_id="O2" value="-35.12" spread="2.63"/>
                    <measurement group_id="O3" value="-40.65" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.90" spread="1.62"/>
                    <measurement group_id="O2" value="-34.98" spread="2.88"/>
                    <measurement group_id="O3" value="-40.27" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.47" spread="1.67"/>
                    <measurement group_id="O2" value="-34.95" spread="2.98"/>
                    <measurement group_id="O3" value="-40.63" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.97" spread="1.71"/>
                    <measurement group_id="O2" value="-35.00" spread="3.05"/>
                    <measurement group_id="O3" value="-40.99" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.87" spread="1.73"/>
                    <measurement group_id="O2" value="-35.05" spread="3.13"/>
                    <measurement group_id="O3" value="-40.88" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.48" spread="1.77"/>
                    <measurement group_id="O2" value="-33.78" spread="3.22"/>
                    <measurement group_id="O3" value="-40.27" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.72" spread="1.71"/>
                    <measurement group_id="O2" value="-32.64" spread="3.13"/>
                    <measurement group_id="O3" value="-40.22" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.00" spread="1.72"/>
                    <measurement group_id="O2" value="-33.61" spread="3.22"/>
                    <measurement group_id="O3" value="-40.67" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.22" spread="1.91"/>
                    <measurement group_id="O2" value="-36.14" spread="3.72"/>
                    <measurement group_id="O3" value="-41.52" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.05" spread="2.10"/>
                    <measurement group_id="O2" value="-34.40" spread="3.95"/>
                    <measurement group_id="O3" value="-40.27" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.44" spread="2.36"/>
                    <measurement group_id="O2" value="-35.73" spread="5.31"/>
                    <measurement group_id="O3" value="-40.99" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.04" spread="2.87"/>
                    <measurement group_id="O2" value="-23.92" spread="9.22"/>
                    <measurement group_id="O3" value="-39.39" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.09" spread="2.96"/>
                    <measurement group_id="O2" value="-17.60" spread="10.66"/>
                    <measurement group_id="O3" value="-35.75" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.91" spread="2.98"/>
                    <measurement group_id="O2" value="-18.20" spread="8.36"/>
                    <measurement group_id="O3" value="-37.43" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.37" spread="2.92"/>
                    <measurement group_id="O2" value="-7.60" spread="9.17"/>
                    <measurement group_id="O3" value="-38.03" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.32" spread="3.69"/>
                    <measurement group_id="O2" value="-16.20" spread="9.01"/>
                    <measurement group_id="O3" value="-35.67" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=21, 1, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.62" spread="6.09"/>
                    <measurement group_id="O2" value="-10.00">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-34.45" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.67" spread="7.31"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-41.67" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Assessment of Arthritis</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment of Arthritis</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.80" spread="1.13"/>
                    <measurement group_id="O2" value="-33.49" spread="2.01"/>
                    <measurement group_id="O3" value="-40.78" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.06" spread="1.08"/>
                    <measurement group_id="O2" value="-34.91" spread="2.20"/>
                    <measurement group_id="O3" value="-43.60" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.34" spread="1.06"/>
                    <measurement group_id="O2" value="-37.15" spread="2.00"/>
                    <measurement group_id="O3" value="-45.09" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.78" spread="1.09"/>
                    <measurement group_id="O2" value="-36.56" spread="2.33"/>
                    <measurement group_id="O3" value="-45.30" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.29" spread="1.07"/>
                    <measurement group_id="O2" value="-41.26" spread="2.01"/>
                    <measurement group_id="O3" value="-46.70" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.28" spread="1.09"/>
                    <measurement group_id="O2" value="-41.92" spread="2.01"/>
                    <measurement group_id="O3" value="-47.58" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.96" spread="1.13"/>
                    <measurement group_id="O2" value="-45.28" spread="2.08"/>
                    <measurement group_id="O3" value="-48.86" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.89" spread="1.14"/>
                    <measurement group_id="O2" value="-47.01" spread="2.05"/>
                    <measurement group_id="O3" value="-49.20" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.03" spread="1.14"/>
                    <measurement group_id="O2" value="-45.70" spread="1.95"/>
                    <measurement group_id="O3" value="-48.99" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.61" spread="1.16"/>
                    <measurement group_id="O2" value="-46.89" spread="2.17"/>
                    <measurement group_id="O3" value="-49.75" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.99" spread="1.28"/>
                    <measurement group_id="O2" value="-48.16" spread="2.23"/>
                    <measurement group_id="O3" value="-49.55" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 83, 342)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.62" spread="1.33"/>
                    <measurement group_id="O2" value="-47.99" spread="2.56"/>
                    <measurement group_id="O3" value="-49.22" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.42" spread="1.47"/>
                    <measurement group_id="O2" value="-47.76" spread="2.39"/>
                    <measurement group_id="O3" value="-49.01" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=231, 78, 309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.99" spread="1.41"/>
                    <measurement group_id="O2" value="-50.19" spread="2.33"/>
                    <measurement group_id="O3" value="-50.04" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.80" spread="1.46"/>
                    <measurement group_id="O2" value="-49.55" spread="2.44"/>
                    <measurement group_id="O3" value="-50.49" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.68" spread="1.39"/>
                    <measurement group_id="O2" value="-49.78" spread="2.58"/>
                    <measurement group_id="O3" value="-50.46" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.52" spread="1.45"/>
                    <measurement group_id="O2" value="-46.33" spread="2.60"/>
                    <measurement group_id="O3" value="-50.23" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.20" spread="1.51"/>
                    <measurement group_id="O2" value="-50.33" spread="2.84"/>
                    <measurement group_id="O3" value="-51.75" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.41" spread="1.72"/>
                    <measurement group_id="O2" value="-50.43" spread="2.98"/>
                    <measurement group_id="O3" value="-51.18" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.10" spread="1.73"/>
                    <measurement group_id="O2" value="-50.97" spread="4.12"/>
                    <measurement group_id="O3" value="-51.07" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.91" spread="2.01"/>
                    <measurement group_id="O2" value="-42.77" spread="6.37"/>
                    <measurement group_id="O3" value="-49.72" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=67, 5, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.57" spread="2.37"/>
                    <measurement group_id="O2" value="-33.60" spread="8.88"/>
                    <measurement group_id="O3" value="-48.46" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.94" spread="2.25"/>
                    <measurement group_id="O2" value="-34.40" spread="10.30"/>
                    <measurement group_id="O3" value="-48.83" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.78" spread="2.17"/>
                    <measurement group_id="O2" value="-31.60" spread="7.92"/>
                    <measurement group_id="O3" value="-50.34" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=58, 5, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.62" spread="2.36"/>
                    <measurement group_id="O2" value="-33.80" spread="9.49"/>
                    <measurement group_id="O3" value="-51.13" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=21, 1, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.05" spread="3.92"/>
                    <measurement group_id="O2" value="-7.00">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-50.95" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.67" spread="1.33"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-37.67" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Assessment of Arthritis Pain</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Assessment of Arthritis Pain</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n= 378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.23" spread="1.40"/>
                    <measurement group_id="O2" value="-27.98" spread="2.39"/>
                    <measurement group_id="O3" value="-32.87" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=372, 105, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.32" spread="1.38"/>
                    <measurement group_id="O2" value="-27.70" spread="2.61"/>
                    <measurement group_id="O3" value="-35.20" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.54" spread="1.34"/>
                    <measurement group_id="O2" value="-30.69" spread="2.32"/>
                    <measurement group_id="O3" value="-37.59" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.34" spread="1.36"/>
                    <measurement group_id="O2" value="-29.03" spread="2.25"/>
                    <measurement group_id="O3" value="-37.06" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.70" spread="1.42"/>
                    <measurement group_id="O2" value="-33.60" spread="2.50"/>
                    <measurement group_id="O3" value="-39.10" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.70" spread="1.45"/>
                    <measurement group_id="O2" value="-32.71" spread="2.56"/>
                    <measurement group_id="O3" value="-39.62" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.98" spread="1.41"/>
                    <measurement group_id="O2" value="-34.39" spread="2.52"/>
                    <measurement group_id="O3" value="-40.19" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.37" spread="1.44"/>
                    <measurement group_id="O2" value="-36.65" spread="2.36"/>
                    <measurement group_id="O3" value="-41.00" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.84" spread="1.51"/>
                    <measurement group_id="O2" value="-37.41" spread="2.28"/>
                    <measurement group_id="O3" value="-40.79" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.49" spread="1.53"/>
                    <measurement group_id="O2" value="-37.65" spread="2.55"/>
                    <measurement group_id="O3" value="-41.38" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.21" spread="1.63"/>
                    <measurement group_id="O2" value="-38.21" spread="2.87"/>
                    <measurement group_id="O3" value="-41.27" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 84, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.61" spread="1.68"/>
                    <measurement group_id="O2" value="-37.99" spread="2.87"/>
                    <measurement group_id="O3" value="-41.48" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.44" spread="1.74"/>
                    <measurement group_id="O2" value="-37.45" spread="2.92"/>
                    <measurement group_id="O3" value="-41.20" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.52" spread="1.78"/>
                    <measurement group_id="O2" value="-37.86" spread="3.04"/>
                    <measurement group_id="O3" value="-41.33" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.05" spread="1.81"/>
                    <measurement group_id="O2" value="-37.07" spread="3.09"/>
                    <measurement group_id="O3" value="-40.79" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.77" spread="1.75"/>
                    <measurement group_id="O2" value="-36.39" spread="2.89"/>
                    <measurement group_id="O3" value="-41.94" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.87" spread="1.73"/>
                    <measurement group_id="O2" value="-37.96" spread="3.24"/>
                    <measurement group_id="O3" value="-42.41" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.85" spread="1.92"/>
                    <measurement group_id="O2" value="-40.21" spread="3.51"/>
                    <measurement group_id="O3" value="-42.97" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.64" spread="2.22"/>
                    <measurement group_id="O2" value="-36.67" spread="3.93"/>
                    <measurement group_id="O3" value="-41.24" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.11" spread="2.59"/>
                    <measurement group_id="O2" value="-38.70" spread="5.25"/>
                    <measurement group_id="O3" value="-40.59" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.61" spread="2.90"/>
                    <measurement group_id="O2" value="-30.38" spread="9.30"/>
                    <measurement group_id="O3" value="-39.97" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.19" spread="2.96"/>
                    <measurement group_id="O2" value="-28.40" spread="12.48"/>
                    <measurement group_id="O3" value="-36.59" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.72" spread="3.08"/>
                    <measurement group_id="O2" value="-21.20" spread="7.85"/>
                    <measurement group_id="O3" value="-35.61" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.54" spread="3.19"/>
                    <measurement group_id="O2" value="-21.20" spread="10.56"/>
                    <measurement group_id="O3" value="-37.30" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.80" spread="3.72"/>
                    <measurement group_id="O2" value="-16.60" spread="11.91"/>
                    <measurement group_id="O3" value="-35.22" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=21, 1, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.19" spread="5.00"/>
                    <measurement group_id="O2" value="-44.00">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-40.36" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.67" spread="9.82"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-34.67" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender/Painful Joint Counts</title>
        <description>This was carried out on 68 joints. Each joints response to pressure/motion was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender/Painful Joint Counts</title>
          <description>This was carried out on 68 joints. Each joints response to pressure/motion was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Tender/painful joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.88" spread="0.48"/>
                    <measurement group_id="O2" value="-10.17" spread="0.95"/>
                    <measurement group_id="O3" value="-11.51" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=373, 105, 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.13" spread="0.51"/>
                    <measurement group_id="O2" value="-10.46" spread="0.90"/>
                    <measurement group_id="O3" value="-11.77" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.06" spread="0.47"/>
                    <measurement group_id="O2" value="-10.75" spread="0.96"/>
                    <measurement group_id="O3" value="-12.55" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.41" spread="0.47"/>
                    <measurement group_id="O2" value="-10.74" spread="0.97"/>
                    <measurement group_id="O3" value="-12.82" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.02" spread="0.50"/>
                    <measurement group_id="O2" value="-12.62" spread="0.89"/>
                    <measurement group_id="O3" value="-13.70" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.32" spread="0.53"/>
                    <measurement group_id="O2" value="-13.05" spread="0.94"/>
                    <measurement group_id="O3" value="-14.03" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.23" spread="0.53"/>
                    <measurement group_id="O2" value="-13.43" spread="0.99"/>
                    <measurement group_id="O3" value="-14.04" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.23" spread="0.55"/>
                    <measurement group_id="O2" value="-13.67" spread="0.94"/>
                    <measurement group_id="O3" value="-14.09" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.45" spread="0.56"/>
                    <measurement group_id="O2" value="-14.00" spread="0.96"/>
                    <measurement group_id="O3" value="-14.34" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.39" spread="0.56"/>
                    <measurement group_id="O2" value="-14.04" spread="1.11"/>
                    <measurement group_id="O3" value="-14.31" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.44" spread="0.60"/>
                    <measurement group_id="O2" value="-13.92" spread="1.03"/>
                    <measurement group_id="O3" value="-14.32" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 83, 342)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.46" spread="0.61"/>
                    <measurement group_id="O2" value="-13.66" spread="1.14"/>
                    <measurement group_id="O3" value="-14.26" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.67" spread="0.65"/>
                    <measurement group_id="O2" value="-13.69" spread="1.07"/>
                    <measurement group_id="O3" value="-14.42" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.01" spread="0.73"/>
                    <measurement group_id="O2" value="-13.30" spread="1.33"/>
                    <measurement group_id="O3" value="-13.83" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.45" spread="0.68"/>
                    <measurement group_id="O2" value="-13.83" spread="1.18"/>
                    <measurement group_id="O3" value="-14.29" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.24" spread="0.70"/>
                    <measurement group_id="O2" value="-14.15" spread="1.20"/>
                    <measurement group_id="O3" value="-14.22" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.41" spread="0.73"/>
                    <measurement group_id="O2" value="-14.06" spread="1.25"/>
                    <measurement group_id="O3" value="-14.33" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.78" spread="0.79"/>
                    <measurement group_id="O2" value="-15.18" spread="1.46"/>
                    <measurement group_id="O3" value="-14.87" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.01" spread="0.87"/>
                    <measurement group_id="O2" value="-14.57" spread="1.42"/>
                    <measurement group_id="O3" value="-14.91" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.79" spread="0.94"/>
                    <measurement group_id="O2" value="-15.67" spread="1.93"/>
                    <measurement group_id="O3" value="-14.98" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.42" spread="1.04"/>
                    <measurement group_id="O2" value="-11.38" spread="2.64"/>
                    <measurement group_id="O3" value="-13.98" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.78" spread="1.56"/>
                    <measurement group_id="O2" value="-11.60" spread="5.46"/>
                    <measurement group_id="O3" value="-13.63" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.11" spread="1.15"/>
                    <measurement group_id="O2" value="-10.80" spread="4.92"/>
                    <measurement group_id="O3" value="-14.80" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.34" spread="1.17"/>
                    <measurement group_id="O2" value="-9.60" spread="4.55"/>
                    <measurement group_id="O3" value="-14.93" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.54" spread="1.27"/>
                    <measurement group_id="O2" value="-9.80" spread="3.95"/>
                    <measurement group_id="O3" value="-15.09" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.55" spread="2.55"/>
                    <measurement group_id="O2" value="-4.00">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-16.96" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.67" spread="1.20"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-8.67" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Counts</title>
        <description>Sixty-six (66) joints, the same as those assessed for tenderness/pain except for the right and left hip joints, were assessed for swelling by palpation using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Counts</title>
          <description>Sixty-six (66) joints, the same as those assessed for tenderness/pain except for the right and left hip joints, were assessed for swelling by palpation using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=378, 105, 483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.67" spread="0.38"/>
                    <measurement group_id="O2" value="-8.69" spread="0.74"/>
                    <measurement group_id="O3" value="-9.46" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=373, 105, 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.12" spread="0.42"/>
                    <measurement group_id="O2" value="-8.54" spread="0.75"/>
                    <measurement group_id="O3" value="-9.78" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=371, 105, 476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.90" spread="0.39"/>
                    <measurement group_id="O2" value="-9.31" spread="0.73"/>
                    <measurement group_id="O3" value="-10.55" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.18" spread="0.40"/>
                    <measurement group_id="O2" value="-9.21" spread="0.67"/>
                    <measurement group_id="O3" value="-10.74" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.33" spread="0.40"/>
                    <measurement group_id="O2" value="-10.46" spread="0.72"/>
                    <measurement group_id="O3" value="-11.13" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=339, 102, 441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.62" spread="0.43"/>
                    <measurement group_id="O2" value="-10.75" spread="0.73"/>
                    <measurement group_id="O3" value="-11.41" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.76" spread="0.44"/>
                    <measurement group_id="O2" value="-11.11" spread="0.74"/>
                    <measurement group_id="O3" value="-11.61" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=323, 102, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.83" spread="0.44"/>
                    <measurement group_id="O2" value="-10.97" spread="0.76"/>
                    <measurement group_id="O3" value="-11.62" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.00" spread="0.46"/>
                    <measurement group_id="O2" value="-11.38" spread="0.80"/>
                    <measurement group_id="O3" value="-11.85" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=309, 92, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.08" spread="0.47"/>
                    <measurement group_id="O2" value="-11.72" spread="0.88"/>
                    <measurement group_id="O3" value="-12.00" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.97" spread="0.50"/>
                    <measurement group_id="O2" value="-11.54" spread="0.84"/>
                    <measurement group_id="O3" value="-11.87" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=259, 83, 342)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.94" spread="0.52"/>
                    <measurement group_id="O2" value="-11.60" spread="0.91"/>
                    <measurement group_id="O3" value="-11.86" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.09" spread="0.56"/>
                    <measurement group_id="O2" value="-11.24" spread="0.87"/>
                    <measurement group_id="O3" value="-11.88" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 (n=232, 79, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" spread="0.64"/>
                    <measurement group_id="O2" value="-11.15" spread="1.16"/>
                    <measurement group_id="O3" value="-11.55" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.90" spread="0.61"/>
                    <measurement group_id="O2" value="-11.74" spread="0.94"/>
                    <measurement group_id="O3" value="-11.86" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=219, 72, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.07" spread="0.61"/>
                    <measurement group_id="O2" value="-11.86" spread="1.04"/>
                    <measurement group_id="O3" value="-12.02" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.17" spread="0.62"/>
                    <measurement group_id="O2" value="-11.67" spread="1.05"/>
                    <measurement group_id="O3" value="-12.05" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 (n=180, 57, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.43" spread="0.70"/>
                    <measurement group_id="O2" value="-12.26" spread="1.24"/>
                    <measurement group_id="O3" value="-12.39" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.36" spread="0.79"/>
                    <measurement group_id="O2" value="-12.48" spread="1.47"/>
                    <measurement group_id="O3" value="-12.38" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 (n=109, 30, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.35" spread="0.82"/>
                    <measurement group_id="O2" value="12.50" spread="1.89"/>
                    <measurement group_id="O3" value="12.38" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.34" spread="0.99"/>
                    <measurement group_id="O2" value="-9.00" spread="2.35"/>
                    <measurement group_id="O3" value="-11.85" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 (n=68, 5, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.74" spread="1.47"/>
                    <measurement group_id="O2" value="-11.00" spread="5.09"/>
                    <measurement group_id="O3" value="-11.68" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.09" spread="1.12"/>
                    <measurement group_id="O2" value="-11.40" spread="5.48"/>
                    <measurement group_id="O3" value="-12.97" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.20" spread="1.15"/>
                    <measurement group_id="O2" value="-10.60" spread="4.70"/>
                    <measurement group_id="O3" value="-13.01" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.58" spread="1.24"/>
                    <measurement group_id="O2" value="-10.00" spread="4.11"/>
                    <measurement group_id="O3" value="-13.30" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 276 (n=22, 1, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.32" spread="2.53"/>
                    <measurement group_id="O2" value="-6.00">Standard error was not calculated due to one participant data available.</measurement>
                    <measurement group_id="O3" value="-14.91" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="0.88"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-8.33" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Physical Functioning</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Physical Functioning</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.87" spread="0.45"/>
                    <measurement group_id="O2" value="5.94" spread="0.76"/>
                    <measurement group_id="O3" value="7.45" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="0.46"/>
                    <measurement group_id="O2" value="6.12" spread="1.01"/>
                    <measurement group_id="O3" value="8.10" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" spread="0.48"/>
                    <measurement group_id="O2" value="6.84" spread="1.05"/>
                    <measurement group_id="O3" value="8.54" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="0.51"/>
                    <measurement group_id="O2" value="7.61" spread="0.93"/>
                    <measurement group_id="O3" value="8.74" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" spread="0.55"/>
                    <measurement group_id="O2" value="8.26" spread="0.88"/>
                    <measurement group_id="O3" value="8.91" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="0.57"/>
                    <measurement group_id="O2" value="8.34" spread="1.09"/>
                    <measurement group_id="O3" value="8.92" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="0.66"/>
                    <measurement group_id="O2" value="7.57" spread="1.18"/>
                    <measurement group_id="O3" value="8.53" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" spread="0.68"/>
                    <measurement group_id="O2" value="7.16" spread="1.36"/>
                    <measurement group_id="O3" value="8.55" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" spread="0.78"/>
                    <measurement group_id="O2" value="8.09" spread="1.25"/>
                    <measurement group_id="O3" value="9.12" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="0.98"/>
                    <measurement group_id="O2" value="5.04" spread="2.27"/>
                    <measurement group_id="O3" value="8.23" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91" spread="1.00"/>
                    <measurement group_id="O2" value="3.27" spread="1.90"/>
                    <measurement group_id="O3" value="8.51" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="1.08"/>
                    <measurement group_id="O2" value="1.64" spread="1.98"/>
                    <measurement group_id="O3" value="8.28" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="1.18"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="10.23" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Physical</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Physical</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.57"/>
                    <measurement group_id="O2" value="5.48" spread="1.00"/>
                    <measurement group_id="O3" value="6.90" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" spread="0.59"/>
                    <measurement group_id="O2" value="6.29" spread="1.06"/>
                    <measurement group_id="O3" value="7.77" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" spread="0.64"/>
                    <measurement group_id="O2" value="7.77" spread="0.92"/>
                    <measurement group_id="O3" value="8.23" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.67"/>
                    <measurement group_id="O2" value="7.47" spread="1.08"/>
                    <measurement group_id="O3" value="7.29" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="0.70"/>
                    <measurement group_id="O2" value="8.15" spread="1.16"/>
                    <measurement group_id="O3" value="7.46" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" spread="0.75"/>
                    <measurement group_id="O2" value="6.77" spread="1.10"/>
                    <measurement group_id="O3" value="7.46" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21" spread="0.80"/>
                    <measurement group_id="O2" value="6.56" spread="1.23"/>
                    <measurement group_id="O3" value="7.05" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" spread="0.77"/>
                    <measurement group_id="O2" value="5.42" spread="1.41"/>
                    <measurement group_id="O3" value="6.90" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="1.01"/>
                    <measurement group_id="O2" value="6.70" spread="1.57"/>
                    <measurement group_id="O3" value="6.61" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="1.37"/>
                    <measurement group_id="O2" value="4.59" spread="2.53"/>
                    <measurement group_id="O3" value="6.25" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.56"/>
                    <measurement group_id="O2" value="-0.48" spread="2.86"/>
                    <measurement group_id="O3" value="5.66" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.58"/>
                    <measurement group_id="O2" value="0.95" spread="2.68"/>
                    <measurement group_id="O3" value="5.74" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.27" spread="5.22"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="22.27" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Bodily Pain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Bodily Pain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="0.48"/>
                    <measurement group_id="O2" value="8.13" spread="0.77"/>
                    <measurement group_id="O3" value="10.40" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.87" spread="0.50"/>
                    <measurement group_id="O2" value="9.63" spread="0.79"/>
                    <measurement group_id="O3" value="11.36" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.19" spread="0.53"/>
                    <measurement group_id="O2" value="10.65" spread="0.75"/>
                    <measurement group_id="O3" value="11.83" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.96" spread="0.56"/>
                    <measurement group_id="O2" value="9.92" spread="0.81"/>
                    <measurement group_id="O3" value="11.47" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="0.59"/>
                    <measurement group_id="O2" value="11.60" spread="1.04"/>
                    <measurement group_id="O3" value="11.41" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.98" spread="0.62"/>
                    <measurement group_id="O2" value="10.42" spread="1.08"/>
                    <measurement group_id="O3" value="11.60" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" spread="0.68"/>
                    <measurement group_id="O2" value="11.15" spread="1.04"/>
                    <measurement group_id="O3" value="11.42" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.82" spread="0.65"/>
                    <measurement group_id="O2" value="11.07" spread="1.11"/>
                    <measurement group_id="O3" value="11.63" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.19" spread="0.85"/>
                    <measurement group_id="O2" value="11.43" spread="1.57"/>
                    <measurement group_id="O3" value="11.25" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.43" spread="1.03"/>
                    <measurement group_id="O2" value="8.52" spread="2.37"/>
                    <measurement group_id="O3" value="11.86" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="1.04"/>
                    <measurement group_id="O2" value="5.25" spread="2.63"/>
                    <measurement group_id="O3" value="10.90" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="1.28"/>
                    <measurement group_id="O2" value="4.50" spread="2.87"/>
                    <measurement group_id="O3" value="10.74" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="5.60"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="7.08" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_General Health</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_General Health</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="0.38"/>
                    <measurement group_id="O2" value="4.24" spread="0.70"/>
                    <measurement group_id="O3" value="5.67" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="0.39"/>
                    <measurement group_id="O2" value="5.00" spread="0.58"/>
                    <measurement group_id="O3" value="6.07" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="0.40"/>
                    <measurement group_id="O2" value="5.20" spread="0.67"/>
                    <measurement group_id="O3" value="6.12" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="0.42"/>
                    <measurement group_id="O2" value="5.35" spread="0.63"/>
                    <measurement group_id="O3" value="6.06" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="0.45"/>
                    <measurement group_id="O2" value="4.82" spread="0.73"/>
                    <measurement group_id="O3" value="5.72" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="0.49"/>
                    <measurement group_id="O2" value="5.36" spread="0.82"/>
                    <measurement group_id="O3" value="5.74" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="0.54"/>
                    <measurement group_id="O2" value="4.38" spread="0.94"/>
                    <measurement group_id="O3" value="5.12" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="0.53"/>
                    <measurement group_id="O2" value="3.93" spread="0.87"/>
                    <measurement group_id="O3" value="5.35" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.61"/>
                    <measurement group_id="O2" value="4.10" spread="1.05"/>
                    <measurement group_id="O3" value="4.57" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="0.87"/>
                    <measurement group_id="O2" value="1.59" spread="1.31"/>
                    <measurement group_id="O3" value="3.42" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="0.96"/>
                    <measurement group_id="O2" value="-1.50" spread="1.90"/>
                    <measurement group_id="O3" value="3.97" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="1.01"/>
                    <measurement group_id="O2" value="-1.03" spread="2.17"/>
                    <measurement group_id="O3" value="3.72" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="4.23"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="-0.94" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Vitality</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Vitality</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="0.59"/>
                    <measurement group_id="O2" value="6.61" spread="0.90"/>
                    <measurement group_id="O3" value="7.20" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="0.58"/>
                    <measurement group_id="O2" value="6.25" spread="0.97"/>
                    <measurement group_id="O3" value="7.02" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.58"/>
                    <measurement group_id="O2" value="7.22" spread="0.89"/>
                    <measurement group_id="O3" value="6.92" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="0.61"/>
                    <measurement group_id="O2" value="6.44" spread="0.98"/>
                    <measurement group_id="O3" value="6.88" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="0.61"/>
                    <measurement group_id="O2" value="6.19" spread="1.11"/>
                    <measurement group_id="O3" value="6.64" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="0.70"/>
                    <measurement group_id="O2" value="6.96" spread="1.26"/>
                    <measurement group_id="O3" value="6.61" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="0.75"/>
                    <measurement group_id="O2" value="5.51" spread="1.15"/>
                    <measurement group_id="O3" value="6.08" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="0.72"/>
                    <measurement group_id="O2" value="4.75" spread="1.27"/>
                    <measurement group_id="O3" value="6.12" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="0.92"/>
                    <measurement group_id="O2" value="5.70" spread="1.62"/>
                    <measurement group_id="O3" value="5.47" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="1.18"/>
                    <measurement group_id="O2" value="5.30" spread="2.47"/>
                    <measurement group_id="O3" value="5.08" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="1.21"/>
                    <measurement group_id="O2" value="-0.60" spread="3.05"/>
                    <measurement group_id="O3" value="4.70" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="1.17"/>
                    <measurement group_id="O2" value="-1.80" spread="3.36"/>
                    <measurement group_id="O3" value="4.21" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.97" spread="8.64"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="14.97" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Social Functioning</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Social Functioning</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="0.60"/>
                    <measurement group_id="O2" value="5.17" spread="1.09"/>
                    <measurement group_id="O3" value="5.03" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="0.62"/>
                    <measurement group_id="O2" value="4.96" spread="1.25"/>
                    <measurement group_id="O3" value="5.44" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.64"/>
                    <measurement group_id="O2" value="5.27" spread="1.14"/>
                    <measurement group_id="O3" value="5.28" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="0.64"/>
                    <measurement group_id="O2" value="4.78" spread="1.31"/>
                    <measurement group_id="O3" value="4.81" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="0.67"/>
                    <measurement group_id="O2" value="6.43" spread="1.19"/>
                    <measurement group_id="O3" value="5.25" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="0.76"/>
                    <measurement group_id="O2" value="5.98" spread="1.11"/>
                    <measurement group_id="O3" value="5.39" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="0.77"/>
                    <measurement group_id="O2" value="3.33" spread="1.39"/>
                    <measurement group_id="O3" value="4.75" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.79"/>
                    <measurement group_id="O2" value="3.84" spread="1.43"/>
                    <measurement group_id="O3" value="4.50" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="0.96"/>
                    <measurement group_id="O2" value="5.63" spread="1.36"/>
                    <measurement group_id="O3" value="4.81" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="1.23"/>
                    <measurement group_id="O2" value="3.31" spread="2.48"/>
                    <measurement group_id="O3" value="4.35" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="1.41"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="4.53" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="1.45"/>
                    <measurement group_id="O2" value="-2.15" spread="2.15"/>
                    <measurement group_id="O3" value="3.95" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.34" spread="9.49"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="14.34" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Emotional</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Emotional</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="0.65"/>
                    <measurement group_id="O2" value="4.98" spread="1.19"/>
                    <measurement group_id="O3" value="6.28" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="0.73"/>
                    <measurement group_id="O2" value="4.40" spread="1.41"/>
                    <measurement group_id="O3" value="6.32" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="0.75"/>
                    <measurement group_id="O2" value="5.49" spread="1.29"/>
                    <measurement group_id="O3" value="6.85" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="0.78"/>
                    <measurement group_id="O2" value="5.54" spread="1.28"/>
                    <measurement group_id="O3" value="5.91" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="0.79"/>
                    <measurement group_id="O2" value="5.96" spread="1.43"/>
                    <measurement group_id="O3" value="6.02" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="0.90"/>
                    <measurement group_id="O2" value="3.98" spread="1.40"/>
                    <measurement group_id="O3" value="5.26" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" spread="0.96"/>
                    <measurement group_id="O2" value="3.74" spread="1.56"/>
                    <measurement group_id="O3" value="4.97" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.90" spread="0.89"/>
                    <measurement group_id="O2" value="4.43" spread="1.49"/>
                    <measurement group_id="O3" value="5.54" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="1.23"/>
                    <measurement group_id="O2" value="4.42" spread="1.91"/>
                    <measurement group_id="O3" value="4.33" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.55"/>
                    <measurement group_id="O2" value="3.49" spread="2.76"/>
                    <measurement group_id="O3" value="4.21" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="1.66"/>
                    <measurement group_id="O2" value="-0.76" spread="4.22"/>
                    <measurement group_id="O3" value="4.33" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="1.74"/>
                    <measurement group_id="O2" value="-0.76" spread="4.22"/>
                    <measurement group_id="O3" value="4.61" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.71" spread="5.78"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="22.71" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Mental Health</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Mental Health</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="0.63"/>
                    <measurement group_id="O2" value="5.38" spread="1.04"/>
                    <measurement group_id="O3" value="6.08" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.65"/>
                    <measurement group_id="O2" value="3.84" spread="1.17"/>
                    <measurement group_id="O3" value="5.69" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="0.64"/>
                    <measurement group_id="O2" value="5.35" spread="1.02"/>
                    <measurement group_id="O3" value="5.64" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="0.70"/>
                    <measurement group_id="O2" value="5.48" spread="1.04"/>
                    <measurement group_id="O3" value="4.94" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="0.68"/>
                    <measurement group_id="O2" value="5.89" spread="1.14"/>
                    <measurement group_id="O3" value="5.38" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="0.77"/>
                    <measurement group_id="O2" value="5.26" spread="1.31"/>
                    <measurement group_id="O3" value="5.49" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="0.84"/>
                    <measurement group_id="O2" value="4.37" spread="1.34"/>
                    <measurement group_id="O3" value="4.91" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="0.76"/>
                    <measurement group_id="O2" value="3.76" spread="1.29"/>
                    <measurement group_id="O3" value="4.79" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.93"/>
                    <measurement group_id="O2" value="5.21" spread="1.75"/>
                    <measurement group_id="O3" value="4.11" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="1.21"/>
                    <measurement group_id="O2" value="4.26" spread="3.04"/>
                    <measurement group_id="O3" value="2.89" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.20"/>
                    <measurement group_id="O2" value="3.32" spread="2.04"/>
                    <measurement group_id="O3" value="3.72" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="1.34"/>
                    <measurement group_id="O2" value="0.00" spread="1.75"/>
                    <measurement group_id="O3" value="3.85" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.78" spread="7.56"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="14.78" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Physical</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Physical</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="0.39"/>
                    <measurement group_id="O2" value="6.09" spread="0.68"/>
                    <measurement group_id="O3" value="7.92" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.39" spread="0.38"/>
                    <measurement group_id="O2" value="7.56" spread="0.70"/>
                    <measurement group_id="O3" value="8.98" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="0.43"/>
                    <measurement group_id="O2" value="8.24" spread="0.72"/>
                    <measurement group_id="O3" value="9.39" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="0.43"/>
                    <measurement group_id="O2" value="8.21" spread="0.76"/>
                    <measurement group_id="O3" value="9.36" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="0.48"/>
                    <measurement group_id="O2" value="8.93" spread="0.77"/>
                    <measurement group_id="O3" value="9.25" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.66" spread="0.49"/>
                    <measurement group_id="O2" value="8.79" spread="0.92"/>
                    <measurement group_id="O3" value="9.45" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="0.54"/>
                    <measurement group_id="O2" value="8.60" spread="0.92"/>
                    <measurement group_id="O3" value="9.09" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="0.54"/>
                    <measurement group_id="O2" value="7.86" spread="1.03"/>
                    <measurement group_id="O3" value="9.10" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="0.65"/>
                    <measurement group_id="O2" value="8.56" spread="1.18"/>
                    <measurement group_id="O3" value="9.29" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.59" spread="0.88"/>
                    <measurement group_id="O2" value="5.37" spread="1.93"/>
                    <measurement group_id="O3" value="8.97" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="0.93"/>
                    <measurement group_id="O2" value="1.91" spread="2.87"/>
                    <measurement group_id="O3" value="8.49" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.72" spread="1.03"/>
                    <measurement group_id="O2" value="2.31" spread="2.27"/>
                    <measurement group_id="O3" value="8.22" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="1.88"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="6.87" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Mental</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
        <time_frame>Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288</time_frame>
        <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Mental</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).</description>
          <population>Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=370, 105, 475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="0.63"/>
                    <measurement group_id="O2" value="4.82" spread="1.01"/>
                    <measurement group_id="O3" value="5.06" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=357, 104, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="0.67"/>
                    <measurement group_id="O2" value="3.38" spread="1.26"/>
                    <measurement group_id="O3" value="4.60" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=331, 102, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="0.66"/>
                    <measurement group_id="O2" value="4.45" spread="1.06"/>
                    <measurement group_id="O3" value="4.54" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315, 99, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="0.69"/>
                    <measurement group_id="O2" value="4.15" spread="1.14"/>
                    <measurement group_id="O3" value="3.75" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=281, 87, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.68"/>
                    <measurement group_id="O2" value="4.53" spread="1.25"/>
                    <measurement group_id="O3" value="4.03" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=242, 80, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="0.80"/>
                    <measurement group_id="O2" value="3.68" spread="1.37"/>
                    <measurement group_id="O3" value="3.76" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 (n=224, 76, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.84"/>
                    <measurement group_id="O2" value="2.24" spread="1.40"/>
                    <measurement group_id="O3" value="3.23" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 (n=213, 70, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.80"/>
                    <measurement group_id="O2" value="2.45" spread="1.41"/>
                    <measurement group_id="O3" value="3.35" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 (n=138, 42, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.99"/>
                    <measurement group_id="O2" value="3.44" spread="1.80"/>
                    <measurement group_id="O3" value="2.38" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 (n=76, 13, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.29"/>
                    <measurement group_id="O2" value="3.14" spread="3.04"/>
                    <measurement group_id="O3" value="1.73" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 (n=65, 5, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="1.27"/>
                    <measurement group_id="O2" value="-0.04" spread="1.81"/>
                    <measurement group_id="O3" value="2.23" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 264 (n=59, 5, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="1.42"/>
                    <measurement group_id="O2" value="-2.25" spread="1.41"/>
                    <measurement group_id="O3" value="2.21" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288 (n=3, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.64" spread="4.01"/>
                    <measurement group_id="O2" value="NA">Mean and standard error were not calculated because no data were available.</measurement>
                    <measurement group_id="O3" value="18.64" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Month 24 in Study A3921044 in Modified Total Sharp Score (mTSS)</title>
        <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented potential improvement. Month 24 (the final visit) in Study A3921044 was taken as the first visit in current study.</description>
        <time_frame>First visit in the study (Month 24 in Study A3921044), Weeks 24, 48, and 96</time_frame>
        <population>Participants who had completed Study A3921044 among all participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Month 24 in Study A3921044 in Modified Total Sharp Score (mTSS)</title>
          <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented potential improvement. Month 24 (the final visit) in Study A3921044 was taken as the first visit in current study.</description>
          <population>Participants who had completed Study A3921044 among all participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=69, 7, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.09"/>
                    <measurement group_id="O2" value="0.50" spread="0.22"/>
                    <measurement group_id="O3" value="0.20" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=64, 7, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.17"/>
                    <measurement group_id="O2" value="1.75" spread="1.16"/>
                    <measurement group_id="O3" value="0.41" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=39, 1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.21"/>
                    <measurement group_id="O2" value="1.00">Standard error was not calculated because there was one participant data.</measurement>
                    <measurement group_id="O3" value="0.42" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to the last participants visit in the study. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for safety evaluation.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>Safety analysis set: all participants who received at least 1 dose of study medication in current study.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to the last participants visit in the study. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for safety evaluation.</description>
          <population>Safety analysis set: all participants who received at least 1 dose of study medication in current study.</population>
          <units>Particiants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with AEs (including SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety observations up to Week 288</time_frame>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patients condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Radicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Device material issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Paget's disease of nipple</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Temporal lobe epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="446" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="293" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="486"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="486"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

